Betting on Tech
Services: Diversified Services
Nuvilex Incorporated (NVLX: OTC)
$0.12 0.01 | 7.27%
06/17/13 - 03:57 PM ET
878.95K / 172.20K
Vol / Avg. Vol:0.11 / 0.11
Open / Prev. Close:0.11 - 0.12
Today's Range:0.02 - 0.22
52 Wk Range:-69.64%
Performance YTD:TheStreet Rating:
Portfolios with NVLX
- Portfolio NameUser Type
Latest NVLX Headlines from TheStreet
- The KonLin Letter Reiterates Upside Potential Of Nuvilex Technologies In May Report 05.09.13 | 09:05 am
- Nuvilex's Subsidiary To Develop "Two-Pronged" Approach To Cancer Treatment 03.07.13 | 09:03 am
- Nuvilex Focused On Positioning Subsidiary, Medical Marijuana Sciences, Inc., To Be A Leading Medical Marijuana Entity By Developing Brain And Pancreatic Cancer Treatments 02.27.13 | 10:02 am
- Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., Presents Further Rationale For Use Of Cannabinoids In Treatments For Pancreatic And Brain Cancers 02.25.13 | 09:02 am
- Nuvilex Reports Cannabinoid-Based Pancreatic Cancer Treatments To Be Developed By Its Subsidiary, Medical Marijuana Sciences, Inc. 02.20.13 | 09:02 am
- Nuvilex Reports Successful Establishment Of Initial Research Cell Bank To Support Late-Phase Pancreatic Cancer Clinical Trial 02.15.13 | 11:02 am
- Nuvilex's Medical Marijuana Subsidiary To Focus On Development Of Treatments For Brain Cancer 02.14.13 | 10:02 am
- Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., Initially Targets Cancer Treatments 02.13.13 | 09:02 am
- Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., To Develop Disease Treatments Based On Cannabinoids 02.12.13 | 10:02 am
- Nuvilex Enters Medical Marijuana Arena 02.11.13 | 03:02 pm
Press Releases for NVLX
- Nuvilex, Inc. Retains Dawson James Financial Services And Moves To Finalize SG Austria Asset Acquisition - Business Wire 05.01.12 | 10:05 am
- KonLin Letter Cites Clinical Trials And Future Partnerships As Rationale For Its Projection Of Strong Future Revenue - Business Wire 04.23.12 | 09:04 am
- April 2012 KonLin Letter Cites Cutting-Edge Technology For Stem Cells And Treatments For Cancer And Diabetes, And Reaffirms Buy Recommendation - Business Wire 04.19.12 | 01:04 pm
- Nuvilex Announces Further Enhancement Of Patent Position - Business Wire 04.11.12 | 10:04 am
- Therapeutic Antibody Producing Cells Encapsulated Using Cell-in-a-Box® Encapsulation Technology Proven Effective For Targeted Treatment Of Various Diseases - Business Wire 04.03.12 | 11:04 am
- Nuvilex Announces Advance In Gene Therapy For Encapsulated Living Cells Using Magnetic Nanoparticles - Business Wire 03.26.12 | 10:03 am
- Cell-in-a-Box® Encapsulation Technology Creates Extensive Applications Within The Stem Cell Arena - Business Wire 03.20.12 | 02:03 pm
- Nuvilex Highlights The Technology And Advances Behind The Cutting-Edge Cell-in-a-Box® Technology Platform - Business Wire 03.19.12 | 02:03 pm
- Completed Clinical Trial Further Indicates Cell-in-a-Box® Encapsulation Technology Has The Potential To Treat A Wide Array Of Solid Tumors - Business Wire 03.15.12 | 10:03 am
- Completed Pancreatic Cancer Phase 1-2 Trial Concluded The Encapsulated Cells Produced Chemotherapy That May Treat Downstream Micro Metastatic Disease - Business Wire 03.13.12 | 01:03 pm
Partner Headlines for NVLX
